undamentalytics Newsletter
Sign in

Prokidney Corp. cash flow statement

In fiscal 2025, Prokidney Corp.'s operations generated −$120m of cash; it spent $15.2m on capital projects, leaving free cash flow of −$135m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−77−90−126−120−141
Depreciation and amortisation34576
Stock-based pay7431292523
Capital spending234301519
Free cash flow−79−124−156−135−160
Free cash flow after stock pay−153−155−185−161−183
Share buybacks0900—
Shares issued001442424

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MNOV vs PROKPROK vs STTKLGVN vs PROK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prokidney Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prokidney Corp.